王境生,庄洪卿,李丰彤,等.贝伐单抗治疗放射性脑坏死的疗效分析[J].中华放射医学与防护杂志,2016,36(9):678-681.Wang Jingsheng,Zhuang Hongqing,Li Fengtong,et al.The efficacy of bevacizumab on the treatment of cerebral radiation necrosis[J].Chin J Radiol Med Prot,2016,36(9):678-681
贝伐单抗治疗放射性脑坏死的疗效分析
The efficacy of bevacizumab on the treatment of cerebral radiation necrosis
投稿时间:2016-04-11  
DOI:10.3760/cma.j.issn.0254-5098.2016.09.008
中文关键词:  贝伐单抗  放射性脑坏死  射波刀  立体定向放疗
英文关键词:Bevacizumab  Cerebral radiation necrosis  Cyberknife  Stereotactic radiotherapy
基金项目:国家自然科学基金(11375048)
作者单位E-mail
王境生 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
庄洪卿 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室 hongqingzhuang@163.com 
李丰彤 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
董洋 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
陈华明 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
宋勇春 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
王晓光 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
袁智勇 300060 天津医科大学肿瘤医院放疗科 国家临床医学中心天津肿瘤防治重点实验室  
摘要点击次数: 3719
全文下载次数: 2561
中文摘要:
      目的 评估贝伐单抗治疗放射性脑坏死的疗效。方法 收集本院2011年6月至2013年2月期间行射波刀立体定向放疗后,影像学诊断为放射性脑坏死患者14例。应用贝伐单抗治疗,剂量5 mg/kg,每3周1次,至少连用3次。以治疗前后脑坏死症状变化、颅内水肿体积、脑坏死体积、脑坏死MRI信号变化为第1观察点。以贝伐单抗治疗的不良反应为第2观察点。结果 治疗后贝伐单抗治疗脑坏死病灶前后水肿指数、脑坏死体积、核磁信号比分别为7.05±6.48、(55.96±32.91)ml、2.70±4.78和3.59±4.74、(26.99±31.40)ml、1.82±0.53,结果差异均有统计学意义(t=3.946、3.952、4.507,P<0.01)。贝伐单抗不良反应较轻,未见2级以上不良反应。结论 贝伐单抗治疗放射性脑坏死安全、有效,值得进一步研究。
英文摘要:
      Objective To evaluate the efficacy of bevacizumab on the treatment of cerebral radiation necrosis. Methods 14 cases were collected from June 2011 to February 2013 in Tianjin Medical Cancer Hospital, who were diagnosed as cerebral radiation necrosis. Patients were treated with bevacizumab a dose of 5 mg/kg, once every 3 weeks, at least 3 times. The changes of symptoms of brain necrosis, the volume of intracranial edema, the volume of brain necrosis, and the MRI signal changes were used as the first observation points. The adverse reactions of bevacizumab were used as the second observation points. Results The edema index, brain necrosis volume, MRI signal ratio before and after bevacizumab treatment brain necrosis lesions were 7.05±6.48, (55.96±32.91) ml, 2.70±4.78 and 3.59±4.74, (26.99±31.40) ml, 1.82±0.53, respectively, with statistical significant differences between the two groups (t=3.946, 3.952, 4.507, P<0.01). The adverse reaction of bevacizumab was less, and there were no more than 2 degree adverse reactions. Conclusions Bevacizumab is effective and safe in the treatment of cerebral radiation necrosis, worthy of further study.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭